The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Type 1 dendritic cells are key to initiate and maintain anti-tumoral T-cell responses in diverse tumour tissues. Our lab focuses on tissue-specific properties of cDC1 in lung tumours, focusing on the ...

While both are called medullary carcinoma, these cancers differ in many ways: ...